🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522680-14-00
Completed Phase I

Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD)

2025-522680-14-00 · tracked via the Priya Life Science EU tracker
Sponsor
Qurient Co. Ltd.
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
24/11/2025
Enrollment target
16
Sites
Spain

Condition studied

Chronic Graft-versus-Host Disease

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522680-14-00 on CTIS ↗ ← All trials in the EU